CMMB Chemomab Therapeutics Ltd

Price (delayed)

$2.28

Market cap

$17.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.04

Enterprise value

$11.18M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis ...

Highlights
CMMB's EPS is up by 46% year-on-year and by 7% since the previous quarter
CMMB's net income is up by 36% year-on-year
CMMB's quick ratio is down by 38% from the previous quarter and by 14% YoY
CMMB's equity is down by 19% from the previous quarter and by 10% YoY

Key stats

What are the main financial stats of CMMB

CMMB stock price

How has the Chemomab Therapeutics stock price performed over time
Intraday
-4.2%
1 week
-13.96%
1 month
5.56%
1 year
-12.31%
YTD
38.18%
QTD
40.74%

Financial performance

How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.91M
Net income
-$7.55M
Gross margin
N/A
Net margin
N/A
Chemomab Therapeutics's operating income has increased by 38% YoY
CMMB's net income is up by 36% year-on-year

Price vs fundamentals

How does CMMB's price correlate with its fundamentals

Growth

What is Chemomab Therapeutics's growth rate over time

Valuation

What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
1.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS is up by 46% year-on-year and by 7% since the previous quarter
CMMB's price to book (P/B) is 71% more than its 5-year quarterly average of 1.2 and 71% more than its last 4 quarters average of 1.2
CMMB's equity is down by 19% from the previous quarter and by 10% YoY

Efficiency

How efficient is Chemomab Therapeutics business performance
CMMB's return on equity is up by 26% year-on-year but it is down by 4% since the previous quarter
The return on assets has increased by 18% year-on-year but it has declined by 3.3% since the previous quarter
Chemomab Therapeutics's return on invested capital has decreased by 10% QoQ but it has increased by 3.9% YoY

Dividends

What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMMB.

Financial health

How did Chemomab Therapeutics financials performed over time
The total liabilities has grown by 40% since the previous quarter and by 9% year-on-year
CMMB's quick ratio is down by 38% from the previous quarter and by 14% YoY
The debt is 100% lower than the equity
CMMB's equity is down by 19% from the previous quarter and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.